Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 49Breast Neoplasms 49Prostatic Neoplasms 47Carcinoma, Non-Small-Cell Lung 47Squamous Cell Carcinoma of Head and Neck 37Lung Neoplasms 29Head and Neck Neoplasms 26Glioma 22Rectal Neoplasms 21Sarcoma 20Neoplasms 20Brain Neoplasms 20Oropharyngeal Neoplasms 16Esophageal Neoplasms 15Uterine Cervical Neoplasms 14Neoplasm Metastasis 14Astrocytoma 13Triple Negative Breast Neoplasms 12Esophageal Squamous Cell Carcinoma 12Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Melanoma 11Gliosarcoma 10Colorectal Neoplasms 10Stomach Neoplasms 9Small Cell Lung Carcinoma 9Lymphoma 9Hodgkin Disease 9Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8

Interventions

atezolizumab 4Specimen Handling 2Magnetic Resonance Spectroscopy 2Etoposide 2Carboplatin 2talazoparib 1lipoarabinomannan 1Radiotherapy 1Radiation 1Lamivudine 1LB100 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Carcinoma × Radiotherapy × 1 year × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡